Comparative Pharmacology
Head-to-head clinical analysis: VASCOR versus VERARING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASCOR versus VERARING.
VASCOR vs VERARING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VASCOR (bepridil) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, reducing contractility and oxygen demand. It also has class I and IV antiarrhythmic properties.
Not available
Bepridil hydrochloride (Vascor) is typically dosed as 200 mg to 400 mg orally once daily.
No established standard dosing. Veraring is not a recognized pharmaceutical agent.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal/hepatic function). May be prolonged in hepatic impairment; unchanged in renal impairment.
Terminal elimination half-life: 4.5 hours (range 3.5-6.0 hours). Clinical context: Steady state achieved within 24 hours; no accumulation with normal renal function.
Primarily hepatic metabolism; ~70% excreted in feces as metabolites, ~30% in urine (largely as metabolites). <2% excreted unchanged in urine.
Renal elimination of unchanged drug and metabolites: 70% (60% unchanged, 40% as glucuronide conjugate); biliary/fecal: 30% (primarily metabolites).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker